Creating a therapy to combat protein issues in neurodegenerative diseases
Official title: Developing an Anti-proteotoxicity Therapy for Neurodegenerative Diseases
Funded at Rezigene, LLC · NIH-10920047 · Data updated 2026-11-12
This study is looking at how problems with proteins in the brain might lead to diseases like Alzheimer's and ALS, and it's trying to find new ways to help our cells better handle these issues, which could lead to better treatments for these tough conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rezigene, LLC NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | September 17, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $349,854 |
| NIH project number | 1R41NS137860-01 |
| Project ID | NIH-10920047 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Alzheimer's disease, frontotemporal dementia, or amyotrophic lateral sclerosis.
✕Less likely to help
Patients with neurodegenerative diseases not related to protein misfolding or aggregation may not benefit from this research.
What this research studies
This research focuses on understanding how protein misfolding and aggregation contribute to neurodegenerative diseases like Alzheimer's and ALS. By using advanced biochemical and genetic techniques, the team aims to identify new molecular targets and develop small molecule compounds that can enhance the cell's ability to manage protein quality control. The goal is to find innovative strategies to prevent and treat these debilitating conditions by harnessing the body's natural defense mechanisms against protein-related stress.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve the treatment of neurodegenerative diseases, potentially slowing their progression or alleviating symptoms.
How similar studies have gone: Previous research has shown promise in targeting protein quality control mechanisms, indicating that this approach could yield significant advancements in treating neurodegenerative diseases.
Where this research is happening
-
Rezigene, LLC
Baltimore, United States Active
Researchers
- Principal investigator: Zhang, Tao — Rezigene, LLC
- Study coordinator: Zhang, Tao
Related research
Other NIH-funded projects on the same topics.
-
Developing small molecules to treat TDP-43 related brain diseases
A potential new drug candidate (XL20) for diseases like Alzheimer’s and other dementias linked to TDP-43 protein problems is being developed and refined for people who live with these conditions.
-
Tau filament structure in Alzheimer’s and related dementias
Aims to map the detailed 3D shapes of tau protein filaments found in human brain diseases to help develop better diagnostics and treatments for Alzheimer’s-related dementias.
-
Targeting RNA Splicing Abnormalities in ALS/FTD
A research team aims to understand and correct abnormal RNA splicing in ALS and related brain diseases to help patients in the future.
-
Blood-brain barrier–friendly imaging agents for neurodegenerative diseases
A researcher team will test new imaging agents that can cross the brain barrier to help detect Alzheimer’s and related diseases earlier and more accurately.
-
Brain cell–derived EV markers to differentiate Alzheimer’s and related dementias
A Mayo Clinic team is testing brain-cell–specific tiny particles in blood to tell apart Alzheimer’s disease and similar dementias using advanced machine-learning analysis.
-
Fisetin approach to reduce vulnerability to community infections in aging veterans
A patient-friendly look at a study testing whether the natural compound fisetin can help aging Veterans stay healthier when they face common infections.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.